Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Boehringer Ingelheim - Focus on NSCLC treatment options

The Future of NSCLC


14 Sep 2020


Boehringer Ingelheim - Focus on NSCLC treatment options


Melissa Johnson


M. Johnson

Author affiliations

  • Lung Cancer Research Program, Sarah Cannon Research Institute/Tennessee Oncology,, Nashville/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.